The Effect of U200 Insulin Administered Via Insulin Pump in Patients with Type 2 Diabetes Mellitus

Presentation Number: SAT 627
Date of Presentation: April 1st, 2017

Michael Spivak* and Naila M Goldenberg
Mercy Health Partners, Mason, OH


Background: Concentrated insulin lispro U200 is not approved by the FDA for continuous subcutaneous insulin infusion therapy via the insulin pumps. Only the Tandem T-Flex insulin pump is available on the market that allows the administration of more than 25/35 units of insulin at a time per bolus compared to Medtronic, Onetouch, Omnipod and Animas insulin pumps. In patients with type 2 diabetes mellitus and high insulin requirements, more than 25 /35 units of insulin per bolus are required, and therefore use of U200 insulin offers an advantage.

Case: We are presenting the first series of four cases of patients with type 2 diabetes mellitus and high insulin requirements, who were switched to lispro U200 insulin administered per insulin pump.

Results: In three out of four patients HgbA1C dropped significantly. In the fourth patient HgbA1C remained in the optimal range. In all four patients the average volume of insulin delivered was reduced significantly, which allowed for less frequent site and cartridge changes. In all four patients there was a weight gain on the average of 10 pounds from the initiation of U200 therapy. Hypoglycemia rate evaluated by 72h continuous glucose monitor was not different before and after the insulin formulation change.

Conclusion: lispro U200 insulin administered as continuous subcutaneous infusion is effective and safe in patients with type 2 diabetes mellitus and high insulin requirements. Longitudinal studies with a larger pool of patients are required to evaluate the long term efficacy and safety of U200 insulin administered via continuous subcutaneous insulin infusion.


Nothing to Disclose: MS, NMG